Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology

被引:86
|
作者
Eikenboom, JCJ [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Haematol, Haemostasis & Thrombosis Res Ctr, NL-2300 RC Leiden, Netherlands
关键词
von Willebrand disease; von Willebrand factor; drug therapy; antibodies; factor VIII; congenital; genetics; mutation;
D O I
10.1053/beha.2001.0139
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
von Willebrand disease type 3 is the most severe form of this condition. Patients present with a moderate-to-severe bleeding tendency. The plasma von Willebrand factor level in these patients is very low or undetectable. Although rare, von Willebrand disease type 3 is of major interest because of its severe clinical presentation, the need for replacement therapy and the risk of occurrence of alloantibodies after the infusion of plasma concentrates. The inheritance of type 3 disease is typically autosomal recessive. The parents are often consanguineous, although compound heterozygous inheritance does occur. The molecular basis of von Willebrand disease type 3 has recently been studied in detail, several molecular defects being identified. This chapter will focus on the clinical and molecular aspects of type 3 von Willebrand disease.
引用
收藏
页码:365 / 379
页数:15
相关论文
共 50 条
  • [31] Molecular diagnosis of von Willebrand disease
    Baronciani, L.
    Goodeve, A.
    Peyvandi, F.
    HAEMOPHILIA, 2017, 23 (02) : 188 - 197
  • [32] Associations of multiple genetic variations with plasma levels of Von Willebrand Factor and clinical phenotype in Iranian patients with Von Willebrand disease type 1
    Zafarani, Alireza
    Tabibian, Shadi
    Barati, Mahmood
    Ghodratnia, Elnaz
    Safa, Majid
    TRANSFUSION AND APHERESIS SCIENCE, 2023, 62 (05)
  • [33] Controversies in the diagnosis of Type 1 von Willebrand disease
    Bowman, M. L.
    James, P. D.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 : 61 - 68
  • [34] VON WILLEBRAND DISEASE: CLINICAL, COAGULOGICAL, MOLECULAR AND GENETIC DATA COMPARISON
    Chernetskaya, D. M.
    Likhacheva, E. A.
    Pshenichnikova, O. S.
    Surin, V. L.
    Zozulya, N., I
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2019, 64 (03): : 246 - 255
  • [35] Clinical experience of prophylactic treatment in von Willebrand disease
    Lethagen, S
    THROMBOSIS RESEARCH, 2006, 118 : S9 - S11
  • [36] Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease
    Rydz, N.
    Grabell, J.
    Lillicrap, D.
    James, P. D.
    HAEMOPHILIA, 2015, 21 (05) : 636 - 641
  • [37] The impact of von Willebrand factor on fibrin formation and structure unveiled with type 3 von Willebrand disease plasma
    Martinez-Vargas, Marina
    Courson, Justin
    Gardea, Luis
    Sen, Mehmet
    Yee, Andrew
    Rumbaut, Rolando
    Cruz, Miguel A.
    BLOOD COAGULATION & FIBRINOLYSIS, 2024, 35 (05) : 256 - 264
  • [38] Von Willebrand Disease type 2 in pregnancy - A critical clinical association
    Simionescu, Anca A.
    Buinoiu, Natalia F.
    Berbec, Nicoleta
    TRANSFUSION AND APHERESIS SCIENCE, 2017, 56 (03) : 269 - 271
  • [39] The Current Understanding of Molecular Pathogenesis of Quantitative von Willebrand Disease, Types 1 and 3
    Yadegari, Hamideh
    Oldenburg, Johannes
    HAMOSTASEOLOGIE, 2020, 40 (01): : 105 - 118
  • [40] Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor
    Sadler, J. E.
    Budde, U.
    Eikenboom, J. C. J.
    Favaloro, E. J.
    Hill, F. G. H.
    Holmberg, L.
    Ingerslev, J.
    Lee, C. A.
    Lillicrap, D.
    Mannucci, M.
    Mazurier, C.
    Meyer, D.
    Nichols, W. L.
    Nishino, M.
    Peake, I. R.
    Rodeghiero, F.
    Schneppenheim, R.
    Ruggeri, Z. M.
    Srivastava, A.
    Montgomery, R. R.
    Federici, A. B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (10) : 2103 - 2114